Gelsolin levels in patients with bronchiolitis.

Hüsrevoglu-Esen F. Altuner-Torun Y, Karakükçü Ç, Köse S, Sehriyaroglu A, Kafadar D, Esen A, Köse M. Gelsolin levels in patients with bronchiolitis. Turk J Pediatr 2018; 60: 286-289. Bronchiolitis is the leading cause of hospitalization in infants. Biomarkers can show severity of the disease and help in clinical management. In this study, the aim was to determine the clinical predictiveness of plasma gelsolin levels (pGSN) in acute bronchiolitis. From December 2013 to May 2014, 52 patients with bronchiolitis (aged < 24 months) were included in this study. Baseline clinical characteristic, complete blood count, C-Reactive Protein, plasma gelsolin levels, chest X-rays were obtained in all patients. The patients were divided into three groups as mild, moderate and severe based on clinical findings. There was no significant difference in pGSN levels between the control group and 3 study groups according to their clinical scores such as mild, moderate and severe bronchiolitis (p > 0.05). Recent studies reported that pGSN levels can be used as a biomarker in sepsis, inflammation and injuries. In this study, we have demonstrated that pGSN level is not a predictive biomarker of bronchiolitis and its severity. Hence, we hypothesized that pGSN levels can be used in bacterial infections rather than viral infections as a biomarker.

Comparing the Efficacy of 7%, 3% and 0.9% Saline in Moderate to Severe Bronchiolitis in Infants.

BACKGROUND: There is no standard treatment option in acute bronchiolitis. 3-7% hypertonic saline (HS) seems to be the effective treatment choice for reducing the hospitalization day. AIMS: To compare the effect of nebulized 7% HS/salbutamol and 3% HS/salbutamol to 0.9% saline/salbutamol. The primary outcome measure was the effect of study drugs on the length of hospital stay (LOS). Secondary outcome measures were safety and efficacy in reducing the clinical severity score (CSS) at the 24 hours of the study. STUDY DESIGN: Prospective, double-blinded randomized clinical study. METHODS: The study consists of 104 infants. Groups were constituted according to the treatment they received: These are, group A - 0.9% saline/salbutamol, group B -3% HS/salbutamol and group C-7% HS/salbutamol. Heart beat, Bronchiolitis CSS and oxygen saturation of the patients were determined before and after nebulization. The patients were monitored for adverse reactions. RESULTS: Length of hospital stay in group A, B and C were as follows; 72.0 (20-288) hours in group A, 64.0 (12-168) hours in group B and 60.0 (12-264) hours in group C. No significant differences was observed among three groups (p>0.05). CONCLUSION: 7% HS and 3% HS does not have any effect to decrease LOS for infants with bronchiolitis.